How did Orthofix Medical's revenue and expenses trend in Q4 2024?

Orthofix Medical's revenue and expenses in Q4 2024 showed a business focus on specific segments with strong gross margins, but net income was negative due to operating expenses.

1. **Revenue Segmentation**: The company's revenue was distributed among various segments, including Global Spine, Spinal Implants, Biologics, and Enabling Technologies, Bone Growth Therapies, Global Extremities, and others.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|OFIX|OFIX.O|Orthofix Medical|20240101-2024|Global Extremities|1.24177E8|185|
|OFIX|OFIX.O|Orthofix Medical|20240101-2024|Global Extremities|8.8403E7|185|
|OFIX|OFIX.O|Orthofix Medical|20240101-2024|Global Extremities|5.7901E7|185|
|OFIX|OFIX.O|Orthofix Medical|20240101-2024|Global Extremities|2.7315E7|185|
|OFIX|OFIX.O|Orthofix Medical|20240101-2024|Spinal Implants, Biologics, and Enabling Technologies|1.08816E8|185|
|OFIX|OFIX.O|Orthofix Medical|20240101-2024|Bone Growth Therapies|5.2477E7|185|
|OFIX|OFIX.O|Orthofix Medical|20240101-2024|Global Extremities|2.7315E7|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|OFIX|OFIX.O|Orthofix Medical|2024 Q1|40.890741409301256|-3.602E7|185|
|OFIX|OFIX.O|Orthofix Medical|2024 Q2|15.175265053517982|-3.3443E7|185|
|OFIX|OFIX.O|Orthofix Medical|2024 Q3|5.090619260491389|-2.7388E7|185|
|OFIX|OFIX.O|Orthofix Medical|2024 Q4|-31.442229638315144|-2.9146E7|185|

|code|Ticker|Name|Date|Gross Profit Margin|Gross Profit Margin YoY|market_code|
|---|---|---|---|---|---|---|
|OFIX|OFIX.O|Orthofix Medical|2024 Q1|67.4637|7.133363082146432|185|
|OFIX|OFIX.O|Orthofix Medical|2024 Q2|67.6581|6.60829254918522|185|
|OFIX|OFIX.O|Orthofix Medical|2024 Q3|68.0063|6.242081402015595|185|
|OFIX|OFIX.O|Orthofix Medical|2024 Q4|68.2791|4.838157415923382|185|

2. **Gross Margin Strength**: All segments maintained a gross margin of 68.28%, indicating efficient production processes and a strong market position in their respective product lines.
3. **Net Income and Operating Expenses**: Despite the strong revenue and gross margin, the company reported a net loss of $29.15 million. This was primarily due to operating expenses that were not offset by revenue, suggesting a need for cost management strategies.
4. **Revenue Distribution**: The revenue distribution among segments shows that Global Spine and Spinal Implants, Biologics, and Enabling Technologies were the highest, followed by Bone Growth Therapies and Global Extremities. This indicates a diversified yet concentrated focus on specific areas of orthopedic care.

In conclusion, Orthofix Medical demonstrated a solid revenue base with strong gross margins across its segments, but high operating expenses led to a negative net income in Q4 2024. The company's focus on cost management and potentially adjusting its expense structure could help improve future financial performance.